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1  |  INTRODUC TION
Emicizumab provides prophylaxis against spontaneous bleeds in pa-
tients with severe haemophilia A (HA) independently of anti- factor VIII 
(FVIII) inhibitor status.1,2 Emicizumab mimics haemostatic activity of 
FVIIIa in the intrinsic tenase complex, but is not neutralised by anti- FVIII 
antibodies.3 The functional and structural characteristics of emicizumab 
lead to strong interferences with coagulation monitoring as these tests 
are optimised for evaluation of plasma FVIII activity.4,5 In the presence 
of emicizumab, all coagulation assays based on an intrinsic pathway ac-
tivation step and chromogenic FVIII assays based on human substrates 
will give misleading results. Subtherapeutic emicizumab plasma levels of 
Received: 26 June 2020  | Revised: 31 December 2020  | Accepted: 14 January 2021
DOI: 10.1111/hae.14264  
O R I G I N A L  A R T I C L E
L a b o r a t o r y  s c i e n c e
Approximation of emicizumab plasma levels in emergency 
situations. A practical approach
Isabell Pekrul1,2  |   Christian Pfrepper3  |   Geli Calatzis2 |   Andreas Giebl4 |   
Annelie Siegemund3 |   Stefanie Grützner4 |   Michael Spannagl2
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.
1Department of Anaesthesiology, Ludwig- 
Maximilian- University of Munich, Munich, 
Germany
2Department of Transfusion Medicine, 
Cell Therapeutics and Haemostaseology, 
Ludwig Maximilian- University of Munich, 
Munich, Germany
3Division of Haemostaseology, Medical 
Department I, University Hospital Leipzig, 
Leipzig, Germany
4Institute for Transfusion Medicine and 
Hemostaseology, Augsburg University 
Clinic, Augsburg, Germany
Correspondence
Isabell Pekrul, Department of 
Anaesthesiology, Ludwig- Maximilian- 





Introduction: A dedicated emicizumab assay based on the modified one- stage factor 
VIII (FVIII) assay (mOSA) is mainly available in haemophilia treatment centres (HTC). A 
method to estimate emicizumab plasma levels based on a widely available assay would 
be desirable, especially for emergency situations.
Aim: A method for emicizumab plasma level approximation (ELA) using a routine FVIII ac-
tivity measurement with standard one- stage assay (sOSA) was developed and evaluated.
Method: Within this pilot study, 59 samples from patients with severe haemophilia A 
with (n = 8) and without (n = 8) inhibitors under emicizumab treatment were analysed 
using sOSA following a manual 1:8 sample pre- test dilution with saline. The sOSA was 
determined in two different laboratories, using two different analyser platforms each.
Results: The results demonstrated an excellent correlation of approximated emici-
zumab plasma levels (ELA) with the emicizumab plasma concentration determined 
with mOSA (r > .9; p < .05). The ELA showed a sensitivity of 93.3% and a specificity 
of 89.6% to predict a pre- defined cut- off- value of ≤30 µg/ml for the discrimination 
between subtherapeutic and therapeutic emicizumab plasma levels.
Conclusion: Approximation of emicizumab levels by standard one- stage FVIII assay 
discriminates between subtherapeutic and therapeutic emicizumab levels and might 
facilitate clinical decision- making in emergency situations, such as bleeding, trauma or 
urgent surgery in case that dedicated emicizumab assays are not available.
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2.5– 10 µg/ml normalise the aPTT for most of the commercially available 
aPTT reagents. Therefore, normalised aPTT results do not indicate emi-
cizumab levels within its therapeutic range. In samples containing emici-
zumab, the aPTT- based standard FVIII one- stage assay (sOSA) reports 
FVIII levels that are well above the reference range, even at subtherapeu-
tic concentrations of the drug.4– 6 Chromogenic FVIII assays using human 
FIXa and FX (CSAh) substrates provide a concentration- dependent effect 
of emicizumab on FVIII activity readout throughout the clinically applied 
dose range for emicizumab.7 A dedicated assay was introduced for the 
quantification of emicizumab levels, which is based on sOSA and uses 
calibrators and controls containing emicizumab. This so- called modified 
one- stage assay (mOSA) is considered as the generally accepted standard 
method for determining emicizumab plasma levels.7 While emicizumab 
has predictable efficacy based on body weight adjusted dosage regimen 
and does not require routine monitoring, the opportunity to determine 
emicizumab concentration is desirable in various situations. These include 
trauma, urgent surgery, bleeding events and situations of unclear patient 
compliance. As mentioned, two specialised methods are available for the 
detection of emicizumab levels. However, these methods are not widely 
available in centres other than haemophilia treatment centres (HTCs). 
In emergency situations, acutely ill patients are mostly allocated to the 
nearest appropriate hospital, which often will not have an attached HTC.
One can expect that in such centres currently three options exist for 
the management of emicizumab treated patients after trauma or break-
through bleeds: a) management of patients without control of emici-
zumab level by any laboratory guidance: in this case, after treatment of 
acute bleeding situations with factor concentrates, possibly unneces-
sary up- titration of emicizumab might be performed, b) performance of 
aPTT and / or FVIII activity measurement using the sOSA levels, which 
can provide misleading results in respect to the emicizumab concentra-
tion in the patient or c) performance of specialised emicizumab assays 
in haemophilia laboratories, which can be logistically challenging, ex-
pensive (when eg samples are transported to specialised centres over 
longer distances) and in particular provide results with a large delay.
We present an alternative procedure for an approximation of emi-
cizumab activity based on the widely available sOSA methodology.
2  |  MATERIAL S AND METHODS
2.1  |  Subjects
This laboratory pilot study was conducted in accordance with the 
recommendations of the University's Ethical Committee and with 
the Declaration of Helsinki. Following the provision of written in-
formed consent to use anonymised left- over samples of citrate 
platelet- poor plasmas from routine coagulation analysis, 16 subjects 
≥18 years of age with severe HA with (n = 8) and without (n = 8) 
inhibitory antibodies were enrolled. We obtained 59 samples cover-
ing different time points during the loading and maintenance dose 
of emicizumab treatment, with (n = 35) and without (n = 24) anti- 
FVIII antibodies. None of the subjects were under concomitant use 
of FVIII- or rFVIIa concentrate at the time of sample acquisition. 
Samples were collected in 3.2% trisodium citrate blood collection 
tubes. The blood was centrifuged at 2500 g/15°C for 15 minutes 
and was stored at minus 80°C until batch analysis.
2.2  |  Assays
In our study, we applied two commercially available assays: the 
mOSA as the standard assay for determination of emicizumab plasma 
levels [µg/ml] and the standard one- stage FVIII activity assay [%] for 
the approximation of emicizumab plasma levels (Figure 1). The assay 
methodologies are described below.
2.3  |  Emicizumab plasma level measurement 
with the modified one- stage assay (mOSA)
Emicizumab plasma levels were measured for all patient samples with 
the mOSA following the manufacturer's protocol for the Werfen ana-
lyser (ACL TOP 600 CTS, Instrumentation Laboratory Company) and 
reagents (SynthASil, SS; HemosIL).7,8 The assay was calibrated against 
emicizumab using commercially available and certified emicizumab 
calibrator and controls (r2 Diagnostics, South Bend, Indiana, United 
States calibrator and controls). The results were reported as µg/ml 
emicizumab plasma concentration. According to the manufacturer's 
validated protocol the mOSA test is performed with a higher auto-
mated sample dilution (1:80; final dilution 1:320) compared to the 
standard one- stage FVIII assay (eg sOSA, ACL TOP/SS; 1:10; final dilu-
tion 1:60). This higher sample dilution allows for the determination of 
emicizumab in a broad, clinically relevant measuring range (between 
10 and 100 μg/ml). The mOSA is considered currently as an accepted 
standard for emicizumab plasma concentration measurement.9
2.4  |  Standard one- stage FVIII assay (sOSA)
Standard one- stage FVIII assays were performed based on the 
manufacturers’ protocols on the ACL TOP and Siemens BCS ana-
lysers (Siemens Healthcare Diagnostics Inc.) with respective rea-
gents and FVIII deficient plasmas (aPTT reagents: SynthASil, SS; 
HemosIL and Pathromtin SL, PSL). The sOSAs are fully automated 
and in routine use, final dilutions of the patients’ plasma samples are 
1:60 for sOSA with SS reagent and 1:40 for sOSA with PSL reagent. 
Results were quantified by reference to plasma calibrators, either 
Siemens Standard Human Plasma (#10446238) or Werfen HemosIl 
(#0020003700) calibrator as appropriate.
2.5  |  Standard one- stage assay for 
approximation of emicizumab plasma levels (ELA)
Adamkewicz et al7 demonstrated that 1 µg/ml emicizumab spiked into 
FVIII deficient plasma showed 8%– 12% surrogate FVIII activity in the 
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sOSA. Therefore, we hypothesised that an approximation of emici-
zumab plasma levels (ELA) could be possible with a comparable as-
sessment as describe for the mOSA; but without a calibration against 
emicizumab.7 In preliminary experiments, we observed that 1:8 diluted 
plasma samples provided a FVIII activity, which resembled the emici-
zumab level in µg/ml of the undiluted sample. Following these consid-
erations, the samples were 1:8 manually pre- diluted with unbuffered 
saline and then analysed using standard one- stage FVIII activity assays 
(sOSAs) as described above. The reported results of the sOSAs would 
be (1) strictly speaking, 1:8 diluted FVIII activities [%] but (2) since the 
plasma sample does not contain FVIII, (3) it seemed to be more correct 
to choose an arbitrary name “ELA [%]”.
To show feasibility and reproducibility, 10 out of 59 samples were 
measured in two different laboratories using the same reagents and 
analyser systems. Patient samples were shipped on dried ice.
2.6  |  Clinical interpretation of emicizumab plasma 
levels (mOSA)
In the clinical study programme for emicizumab, the investigated dos-
age regimes resulted in maintenance plasma levels ranging between 
~30 and 80 µg/ml plasma concentration in the.2,7,10,11 Therefore, the 
emicizumab plasma levels and the ELAs will be stratified as subthera-
peutic when ≤30 µg/ml and as therapeutic when >30 µg/ml.
2.7  |  Quality control of mOSA and sOSA
For this pilot study, all results were measured with certified 
and standardised assays and analyser systems. The laboratories 
participate in internal and external quality control programmes. 
Intra- and inter- day percent coefficient of variance (CV) for sOSAs, 
and the mOSA are below 10%.
2.8  |  Statistical analysis
Statistical analysis was performed using GraphPad software and 
MS Excel (Microsoft Corporation). Descriptive statistics were per-
formed and presented as median and interquartile range (IQR). 
Where applicable, normality testing was carried out using the 
Kolmogorow- Smirnow goodness of fit test. Normal distributed data 
were analysed using students t- test for unpaired data with differ-
ent variances (analysis between inhibitor and non- inhibitor patients). 
A p- value of <.05 was considered statistically significant. Pearson's 
correlation coefficient (r) was calculated to show the strength of the 
linear relationship between the ELA and the corresponding emici-
zumab plasma levels for each analysed batch and aPTT reagent. For 
agreement analysis of the mOSA and the ELA, the Cohens coeffi-
cient, (κ) has been used.11 No further formal hypothesis testing has 
been performed in this pilot study.
3  |  RESULTS
3.1  |  Emicizumab plasma levels results with mOSA
The results cover the whole range of measurement (min. 0∣max. 
94 µg/ml). The median is at 27 µg/ml (IQR 38; Q1 5∣Q3 53 µg/ml) 
meaning that 50% of data points approximately encompass subther-
apeutic and 50% therapeutic emicizumab levels.
F I G U R E  1  In Germany, for instance, approximately 90 laboratories offer sOSA. Most of these laboratories are associated or cooperate 
with hospitals. There are far fewer HTCs with specialised coagulation laboratories, providing the full laboratory diagnostic set for patients 
treated with emicizumab. Figure 1 gives an overview of the different assays, calibrators, and their reported test results. The emicizumab 
plasma level approximation with sOSA (ELA) might be useful in emergency situations when dedicated emicizumab assays are not available. 
Abbreviations: ELA [%] emicizumab plasma level approximation (=1:8 pre- diluted (saline) plasma samples analysed with sOSA)), HTC 
haemophilia treatment centre, mOSA modified one- stage assay, sOSA standard FVIII one- stage assay. # in the absence of emicizumab 
calibrators
Coagulation laboratory Coagulation laboratory Haemophilia treatment centre 
Routine assay Absence of mOSA# Routine assay 
1:8 pre-diluted (saline) 
patient’s plasma  












plasma level [µg/ml] 
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3.2  |  Emicizumab level approximation (ELA)— 
comparison to mOSA
The results of sOSA measurement after 1:8 unbuffered saline 
pre- dilution of the plasma samples were expressed as emicizumab 
plasma level approximation (ELA [%]). The ELA results obtained by 
sOSA- SS and sOSA- PSL ranged between 0 and 103% (median 32%; 
IQR 44; Q1 17∣Q3 61) and 0%– 71% (median 22%; IQR 32; Q1 10∣Q3 42), 
respectively. A strong and significant linear association was shown 
with the Pearson's correlation coefficient for each aPTT reagent 
(SynthASil®, Pathromtin®) and batch (Figure 2A). No significant dif-
ference in the ELA results has been observed between the inhibitor 
and non- inhibitor group. We observed an up to 1.25- fold variability 
of ELA results between aPTT reagents and after batch change of the 
SynthASil- reagent an up to 2- fold variability. It was hypothesised that 
the approximate value could be of use for decision- making at a cate-
gorical level, for example subtherapeutic or therapeutic emicizumab 
level. Therefore, data were stratified depending on the value to the 
subtherapeutic or therapeutic range for further analysis. The sen-
sitivity and specificity calculation for the cut- off point of 30 µg/ml 
(95% CI 25.4∣34.5 µg/ml) was 93.3% and 89.6%, respectively. For 
agreement analysis of the ELA and the mOSA, the Cohens coeffi-
cient was calculated and demonstrated a substantial agreement of 
the results (Cohen coefficient κ of 0.8) (Table 1). 10 samples were 
analysed in two different laboratories with the same analyser plat-
forms and reagents. The results confirmed that ELAs were able to 
discriminate between subtherapeutic and therapeutic emicizumab 
plasma levels (Figure 2B).
F I G U R E  2  (A) Figure 2a shows 
emicizumab plasma levels [µg/ml] 
versus ELA [%] = emicizumab level 
approximation for two different aPTT 
reagents: SS reagent (circles) and PSL 
reagent (triangles), measured in two 
batches (batch 1 open circle/triangle, 
batch 2 closed circle/triangle). After lot- 
change for SS reagent and FVIII deficient 
plasma, we observed systematically lower 
results for batch 2. For the PSL reagent, 
the results of batch 1 and 2 show minor 
shifts between batches. Grey areas 
indicate (l) subtherapeutic (r) therapeutic 
emicizumab plasma concentrations. 
Abbreviations: ELA, emicizumab plasma 
level approximation; PSL, Pathromtin®; 
SS, SynthASil®; #ELA results obtained 
with sOSA using manually 1:8 pre- 
diluted (saline) patient plasma sample. 
(B) ELAs (n = 10; inhibitor sample n = 7, 
non- inhibitor samples n = 3) determined 
in two different laboratories with the 
same coagulation analysers and reagents 
showed comparable correlations with 
mOSA emicizumab plasma levels and were 
able to differentiate between sub- and 
therapeutic emicizumab plasma levels. 
Grey areas indicate (l) subtherapeutic 
(r) therapeutic emicizumab plasma 
concentrations. Abbreviations: ELA, 
emicizumab plasma level approximation; 
PSL, Pathromtin®; SS, SynthASil®; 
#ELA results obtained with sOSA using 
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4  |  DISCUSSION
Emicizumab as a subcutaneous haemophilia A (HA) medication with 
a long half- life and predictable pharmacokinetics, is applied in body 
weight adjusted dosing and no routine monitoring is required.1,2,12,13 
A specialised laboratory assay for determination of the emicizumab 
concentration is commercially available and is widely used in haemo-
philia treatment centres (HTCs). Emicizumab leads to increased qual-
ity of life and mobility of HA patients, and therefore, patients can be 
expected to expose themselves to more risky situations and to re-
side in larger distance from their haemophilia centres. In emergency 
situations, like trauma, breakthrough bleeds or in case of emergency 
surgery most patients will be admitted in non- specialised hospitals 
for medical treatment. In this setting, a specialised assay for emi-
cizumab monitoring will often not be available. However, for the 
clinical decision- making the information whether the emicizumab 
level is therapeutic or subtherapeutic might still be beneficial.14,15 
Clinical studies have shown that most patients under emicizumab 
maintenance therapy have emicizumab plasma levels of 30– 80 µg/
ml.1,2,12,13 Within this concentration range, no difference of efficacy 
of the treatment was observed. This means that while the deter-
mination of a subtherapeutic or treatment level of emicizumab can 
have therapeutic consequences, the exact quantification of the 
plasma concentration of emicizumab will mostly not be required in 
this emergency setting.
Here, we demonstrated a method for emicizumab plasma level 
approximation using the widely available standard one- stage FVIII 
activity assay methodology. The emicizumab plasma levels (ELAs) 
were approximated by diluting patients’ plasma samples 1:8 in un-
buffered saline and then determining FVIII levels using standard 
methodologies. As no FVIII was present in the samples, the results 
were expressed as the ELA.
Our study demonstrated an excellent correlation of ELA with the 
emicizumab plasma concentration. Using a cut- off value of ≤30 µg/
ml subtherapeutic from therapeutic levels were discriminated with 
a sensitivity and specificity of 93.3 and 89.6%, respectively. The 
agreement between ELA and emicizumab concentration resulted in 
a Cohen coefficient κ of 0.8; demonstrating a substantial agreement 
of results. Stronger variations of ELA were seen at emicizumab levels 
above 30 µg/ml, which are however of little clinical relevance.
The ELA is not a substitute to the modified one- stage assay 
(mOSA) or the chromogenic FVIII determination using human 
substrates (CSAh). Therefore, some limitations should be noted: 
Experimental data using two different aPTT reagents, have been 
presented which indicate the utility of such an assay. Now clinical 
experiences with this strategy are required to fully evaluate the 
benefits and limitations of this strategy. In addition, further stud-
ies are desirable to confirm performance of this assay when differ-
ent aPTT reagents and batches are applied. It must be – – expected 
that a high FVIII activity in the patient sample, will lead to false- 
high ELA level. However, this is also true for the mOSA which— as 
the ELA— is also based on the one- stage FVIII assay.16,17 Obviously, 
the CSAh, using human substrates, is strongly influenced by the 
presence of FVIII in the sample. This limitation of the ELA should 
therefore be taken into account, when emicizumab treated pa-
tients received FVIII concentrates in addition, for example in the 
case of bleeding complications or surgery. One strategy would be 
to determine the ELA before the FVIII is administered. Due to its 
long half- life, the emicizumab level should then be stable during 
the clinical course of the patient. If the level of the FVIII given shall 
be quantified, this could be performed using a chromogenic FVIII 
assay using bovine compounds (in case such assay is available in 
the institution).
In addition, as shown in our investigations, there can be variations 
of the ELA based on the used reagents and instrumentation applied for 
the sOSA. We observed an up to 1.25- fold variability of ELA results be-
tween aPTT reagents and after batch change of the SynthASil- reagent 
an up to 2- fold variability. However, for the discrimination between 
subtherapeutic and therapeutic concentrations these variabilities had 
little effect. Therefore, despite the presented assay and batch influence 
TA B L E  1  The agreement between ELA and emicizumab concentration resulted in a Cohen coefficient κ of 0.8; demonstrating a 
substantial agreement of results
#ELA results obtained using sOSA using 1:8 manually pre- diluted (saline) patient plasma sample. 
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the ELA concept would still provide valuable orientation in the ab-
sence of dedicated emicizumab assays. Still, further evaluations would 
be desirable in subsequent studies to determine FVIII assays more or 
less suitable for the ELA determination. Adamkewicz et al. reported a 
quite uniform dose- response of emicizumab using 13 different aPTT 
reagents. 7 Therefore, it can be expected that the ELA methodology 
should allow to be adapted to a large number of aPTT reagents in the 
market.
Drugs or diseases which can interfere with the sOSA, such as direct 
oral anticoagulants and lupus anticoagulants, can also be expected to 
influence ELA and the mOSA, however potentially to a lesser extend 
due to the high sample dilution applied in these two methodologies.
Our pilot study presents a practical approach for the approxi-
mation of emicizumab plasma levels with a reasonable accuracy. In 
emergency situations, the ELA might beneficially contribute to the 
following aspects of clinical decision- making, when specific assays 
for emicizumab are not available:
The aPTT is oversensitive to emicizumab and normalises even 
at very low emicizumab levels (2,5 µg/ml).7,18,19 Thus, the aPTT can 
be in its reference range up to six months after the last emicizumab 
injection and is therefore an inadequate indicator for its haemo-
static activity or the patient's therapy compliance. In contrast, ELA 
could help identify missing patient compliance, the development of 
an anti- drug antibody and a subtherapeutic emicizumab dose due 
to haemodilution following trauma- induced bleeding. The conse-
quence of the detection of a subtherapeutic ELA in an emicizumab 
patient may include education of the patient, with the investigation 
of a potential missing patient compliance, subsequent analyses in re-
spect to a potential inhibitor formation to emicizumab or simply the 
application of an additional emicizumab dose.
From a laboratory perspective the presented methodology is 
simple enough to be reliably communicated to non- specialised 
laboratory staff with a high likelihood of success. In this respect, 
we avoided variations making the ELA more complicated or expen-
sive, such as diluting the patient sample in FVIII deficient plasma 
as this could interfere with the intended application of the ELA 
method in emergency situations. However, one should be aware of 
potential risks such as the reporting of a false FVIII activity in the 
patients’ medical file. This risk is not unique to the ELA method, 
because also aPTT, thrombelastography or FVIII results in the nor-
mal range could be misinterpreted by the treating physicians.
5  |  CONCLUSION
The approximation of emicizumab plasma level (ELA) is easy to perform 
using a standard one- stage FVIII activity assay (sOSA) without substance- 
specific calibration, following manual pre- dilution of the plasma sample 
with saline. We demonstrated that the ELA allows for the discrimination 
between subtherapeutic and therapeutic emicizumab levels. Eventually, 
in emergency situations when a dedicated emicizumab assay is not 
available, the ELA can give valuable information on the patient's hae-
mostatic situation and support clinical decision- making.
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